THE CHEK2 del5395 IS A FOUNDER MUTATION
WITHOUT DIRECT EFFECTS FOR CANCER RISK
IN THE LATVIAN POPULATION
Plonis J*, Kalniete D, Nakazawa-Miklasevica M, Irmejs A, Vjaters E, Gardovskis J, Miklasevics E
*Corresponding Author: Juris Plonis, M.D., Institute of Oncology, Riga Stradins University, Dzirciema 16, LV-
1007, Riga, Latvia. Tel: +371-2915-9476. Fax: +371-6706-9904. E-mail: juris.plonis@inbox.lv
page: 33
|
|
REFERENCES
1. Bartek J, Lukas J. Chk1 and Chk2 kinases in
checkpoint control and cancer. Cancer Cell.
2003; 3(5): 421-429.
2. Walsh T, Casadei S, Coats KH, Swisher E, Stray
SM, Higgins J, et al.. Spectrum of mutations in
BRCA1, BRCA2, CHEK2, and TP53 in families
at high risk of breast cancer. JAMA. 2006;
295(12): 1379-1388.
3. Cybulski C, Wokołorczyk D, Huzarski T, Byrski
T, Gronwald J, Górski B, et al. A large germline
deletion in the Chek2 kinase gene is associated
with an increased risk of prostate cancer. J Med
Genet. 2006; 43(11): 863-866.4. Cybulski C, Wokołorczyk D, Huzarski T, Byrski
T, Gronwald J, Górski B, et al. A deletion in
CHEK2 of 5,395 bp predisposes to breast cancer
in Poland. Breast Cancer Res Treat. 2007;
102(1): 119-122.
5. Myszka A, Karpinski P, Slezak R, Czemarmazowicz
H, Stembalska A, Gil J, et al. Irrelevance of
CHEK2 variants to diagnosis of breast/ovarian
cancer predisposition in Polish cohort. J Appl
Genet. 2011; 52(2): 185-191.
6. Cybulski C, Wokołorczyk D, Cybulski C,
Wokołorczyk D, Kładny J, Kurzawski G, et
al. Germline CHEK2 mutations and colorectal
cancer risk: Different effects of a missense and
truncating mutations. Eur J Hum Genet. 2007;
15(2): 237-241.
7. Cybulski C, Masojc B, Oszutowska D, Jaworowska
E, Grodzki T, Waloszczyk P, et al.
Constitutional CHEK2 mutations are associated
with a decreased risk of lung and laryngeal cancers.
Carcinogenesis. 2008; 29(4): 762-765.
8. Eglite ME, Zvagule TJ, Rainsford KD, Reste JD,
Curbakova EV, Kurjane NN. Clinical aspects of
the health disturbances in Chernobyl Nuclear
Power Plant accident clean-up workers (liquidators)
from Latvia. Inflammo-pharmacology.
2009; 17(3): 163-169.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
